buspirone has been researched along with Neoplasms in 3 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Buspirone, a non-benzodiazepine anxiolytic which does not suppress respiration and has proven efficacy in the treatment of generalized anxiety disorder, has been suggested to relieve the sensation of dyspnea in patients with COPD." | 9.22 | Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. ( Banerjee, TK; Bushunow, PW; Dakhil, SR; Dudgeon, DJ; Flannery, MA; Garland, SN; Heckler, CE; Hopkins, JO; Kirshner, JJ; Morrow, GR; Peoples, AR; Peppone, LL; Roscoe, JA, 2016) |
| " Buspirone, a non-benzodiazepine anxiolytic which does not suppress respiration and has proven efficacy in the treatment of generalized anxiety disorder, has been suggested to relieve the sensation of dyspnea in patients with COPD." | 5.22 | Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study. ( Banerjee, TK; Bushunow, PW; Dakhil, SR; Dudgeon, DJ; Flannery, MA; Garland, SN; Heckler, CE; Hopkins, JO; Kirshner, JJ; Morrow, GR; Peoples, AR; Peppone, LL; Roscoe, JA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Takwale, AD | 1 |
| Jo, SH | 1 |
| Jeon, YU | 1 |
| Kim, HS | 1 |
| Shin, CH | 1 |
| Lee, HK | 1 |
| Ahn, S | 1 |
| Lee, CO | 1 |
| Du Ha, J | 1 |
| Kim, JH | 1 |
| Hwang, JY | 1 |
| Peoples, AR | 1 |
| Bushunow, PW | 1 |
| Garland, SN | 1 |
| Heckler, CE | 1 |
| Roscoe, JA | 1 |
| Peppone, LL | 1 |
| Dudgeon, DJ | 1 |
| Kirshner, JJ | 1 |
| Banerjee, TK | 1 |
| Hopkins, JO | 1 |
| Dakhil, SR | 1 |
| Flannery, MA | 1 |
| Morrow, GR | 1 |
1 trial available for buspirone and Neoplasms
| Article | Year |
|---|---|
Buspirone for management of dyspnea in cancer patients receiving chemotherapy: a randomized placebo-controlled URCC CCOP study.
Topics: Anti-Anxiety Agents; Anxiety; Anxiety Disorders; Buspirone; Disease Management; Double-Blind Method; | 2016 |
2 other studies available for buspirone and Neoplasms
| Article | Year |
|---|---|
Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Male | 2020 |
Drug watch providing essential information.
Topics: Buspirone; Humans; Lactation; Metronidazole; Neoplasms; Nicotine; Paclitaxel; Substance-Related Diso | 1994 |